Improving HER2 detection in breast cancer with new testing method
Part of Cancer, Skin clinical trials.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with breast cancer after January 1, 2022
- You already had surgery and chemotherapy (if needed) for your breast cancer
- You agree to let researchers look at your medical records and tissue samples
- Your cancer is either HER2-zero or HER2-low based on standard tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.